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ABSTRAK
Tujuan: meneliti tentang faktor-faktor yang berhubungan dengan probabilitas drop out yang lebih tinggi 
bagi pasien HIV, dan potensi produktifitas yang hilang akibat drop out tersebut. Metode: Kami menganalisis 
data dari 658 pasien HIV dari sebuah database di sebuah rumah sakit rujukan utama di kota Bandung, Jawa 
Barat, Indonesia dari tahun 2007-2013. Pertama, kami menggunakan metode analisis regresi probit dan 
mengikutsertakan, antara lain, variabel berikut: status pasien (aktif atau drop out), CD4 cell count, TB dan 
infeksi oportunistik (IO), status bekerja, jenis kelamin, pengalaman sebagai penasun, dan dukungan dari keluarga 
dan peers. Kedua, kami menggunakan data tingkat drop out dari database kami dan tingkat penurunan CD 4 
cell count dari studi lain untuk mengestimasi produktifitas yang hilang akibat drop out. Hasil: CD4 cell count 
yang rendah diasosiaikan dengan probabilitas drop out yang lebih tinggi. Dukungan dari peers, hidup bersama 
keluarga, dan menderita TB diasosiasikan dengan probabilitas drop out yang lebih rendah. Produktifitas yang 
hilang pada tingkat nasional akibat drop out (dank arena tingkat CD 4 cell count yang menurun) dapat mencapai 
US$365 juta (menggunakan upah rata-rata). Kesimpulan: pertama, karena tingkat CD 4 cell count yang rendah 
diasosiasikan dengan probabilitas drop out yang lebih tinggi,kami merekomendasikan (untuk mengoptimasikan) 
pemberian ARV dini pada tingkat CD 4 cell count yang lebih tinggi, melibatkan pemberian layanan HIV di tingkat 
komunitas. Kedua, dukungan keluarga dan peer harus diperkuat untuk mendukung kesuksesan dari perawatan 
HIV. Ketiga, drop out  dari layanan ART akan menyebabkan hilangnya produktifitas yang cukup besar.
Kata kunci: HIV, sosial-ekonomi, terapi antiretroviral, Indonesia, drop out.
ABSTRACT
Aim: this study reported various factors associated with a higher probability of HIV patients drop out, 
and potential productivity loss due to HIV patients drop out. Methods: we analyzed data of 658 HIV patients 
from a database in a main referral hospital in Bandung city, West Java, Indonesia from 2007 to 2013. First, we 
utilized probit regression analysis and included, among others, the following variables: patients’ status (active 
or drop out), CD4 cell count, TB and opportunistic infection (OI), work status, sex, history of injecting drugs, 
and support from family and peers. Second, we used the drop out data from our database and CD 4 cell count 
decline rate from another study to estimate the productivity loss due to HIV patients drop out. Results: lower CD4 
cell count was associated with a higher probability of drop out. Support from family/peers, living with family, 
and diagnosed with TB were associated with lower probability of drop out. The productivity loss at national 
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level due to treatment drop out (consequently, due to CD4 cell count decline) can reach US$365 million (using 
average wage). Conclusion: first, as lower CD 4 cell count was associated with higher probability of drop out, 
we recommend (to optimize) early ARV initiation at a higher CD 4 cell count, involving scaling up HIV service 
at the community level. Second, family/peer support should be further emphasized to further ensure treatment 
success. Third, dropping out from ART will result in a relatively large productivity loss.
Keywords: HIV, socio-economic, antiretroviral therapy, Indonesia, drop out.
INTRODUCTION
Indonesia is experiencing a fast increase in 
HIV prevalence (estimated <0.1% in 2001 to 
0.4% in 2012)1 and a change in the HIV epidemic- 
whereas it was previously concentrated within 
the intravenous drug users (IDUs) and their 
couples, and now it moves to general population. 
The percentage of HIV transmission through 
injecting drug use decreased from 53% in 2001-
2005 to 34% in 2011, while the heterosexual 
transmission rose from 37% to 71% within the 
same period.2
Indonesia’s response to the epidemic have 
started since the first domestic case was detected 
which included the continuing support for 
care and treatment programs.2,3 In accordance, 
the need for antiretroviral therapy (ART) was 
expected to reach around 87,000 patients in 
2014.4 Although the availability of ART in 
Indonesia is increasing2, drop out rate is still a 
significant issue.5–7 In a more specific context, 
this phenomenon is apparent in a clinic within 
a main referral hospital in West Java. Although 
this clinic has been successful in increasing 
the quality of HIV-care and reducing mortality 
rate, it is still facing challenges in reducing a 
high dropout rate, which is only slightly lower 
than the national estimate.6,8 This is crucial as 
the success of ART will increase quality of life 
(QoL), productivity, and physical and emotional 
health.9–11 These factors in the end will influence 
the survival of patients.12
Given the importance of HIV patients drop 
out, there is an urgency to answer the following 
questions: 1) What are the factors influencing 
the HIV patients drop out rate in Indonesia?, 
and 2) What is the potential economic impact? 
There has been a number of studies trying to 
pinpoint the reasons underlining treatment 
drop out or non-adherence. Some local studies 
suspected socio-economic factors as possible 
causes13,14, while others suspected psycho-social 
and biomedical factors5,7,15, or simply patients’ 
error (e.g. forget to take medication).16 These 
factors have also been explored by international 
studies.17–21 The results were varied from all of 
these studies, and required further confirmation 
to apply in a specific context. Understanding 
the factors influencing dropout rate will provide 
valuable input in providing better service and 
policy input.6 The research on economic impact 
of drop out, on the other hand, still limited. This 
is a very important point for Indonesia since HIV 
patients drop out is still a problem.
This  s tudy analyzed the  pa t ien ts ’ 
socioeconomic, demographic, and clinical 
characteristics, and explored whether these 
characteristics were associated with the higher/
lower probability of HIV patients drop out. 
This study also estimated the economic impact 
of drop out in terms of productivity loss. This 
study was unique for four reasons. First, to our 
knowledge, studies exploring the factors causing 
HIV patients dropouts in Indonesia is limited. 
Second, our study utilizes data from a large 
number of patients’ medical record as a part of 
a larger cohort database owned by the clinic, 
providing a lot of valuable information otherwise 
unattainable. Third, the clinic in our study is 
utilized by patients from all over the province 
(and in some cases beyond the province), which 
gives it a pivotal role in providing evidence for 
policy making. Fourth, this study estimates the 
productivity loss as the impact of drop out to 
provide evidence for policy makers.
METHODS
Study Setting and Study Population
The study was conducted in Bandung, at an 
HIV/AIDS clinic in the largest public referral 
Vol 48 • Number 3 • July 2016                                                                               HIV patients drop out in Indonesia
209
and teaching hospital in West Java province 
(43 million inhabitants). The clinic is visited 
by high risk group of patients and the general 
population, and deliver HIV-related services 
such as voluntary counseling and testing, ART, 
and sexually transmitted infections services. 
The clinic operates at full capacity because it 
is among the few clinics that deliver ART in 
Bandung. The clinic generates its own revenues 
through government, hospital, and private 
funding. The ART-related services are free, 
except for hospitalization and the registration fee.
Data Collection and Analysis
We utilized the database of a clinic within 
a main referral hospital in Bandung city, West 
Java, Indonesia (2007-2013). Out of the data of 
8,184 HIV patients, we only included the data 
of 658 patients due to incomplete data set. We 
extracted data related to four categories: patient’s 
current status, socioeconomic, demographic, and 
clinical characteristics. The detailed variables list 
from each category is presented in Table 1. We 
used Microsoft Excel 2013 and STATA 13 for 
data cleaning and analysis. We utilized probit 
regression analysis to determine the influence 
of each factor. We only used the patients’ clinic 
ID number throughout the analysis, and none of 
patients’ personal identification is used.
We also combined our dropout rate data and 
the CD4 decline rate from another study within 
the same clinic to estimate the productivity loss 
due to drop out from HIV treatment. We estimated 
the length of time it took for the CD4 cell count 
of patients who drop out to reach approximately 
50 cells/mm3 (assuming that they do not seek any 
treatment after they drop out). We assumed that 
patients can no longer be productive afterwards 
due to the onset of various opportunistic 
infections as patients with CD4 cell count lower 
than 100 cells/mm3 was considered to experience 
immunological failure.23 The productivity loss 
was then measured by the loss of income from the 
moment patients reach the CD4 cell count of 50 
cells/mm3 until the end of productive age using 
Microsoft Excel 2013. We used average and 
minimum wage from a publication by ILO24, and 
we assumed the productive age of 15-64 years 
as stated by Bureau of Statistics of Indonesia 
Table 1. List of variables
Variable List Definition Type
Patient Status (dependent variable) 0 = active, 1= drop out Dummy
Socioeconomic characteristics
 - Age Absolute Continuous
 - Sex 0 = female, 1= male Dummy
 - Employment status 0 = unemployed, students, housewife, 
1 = employed 
Dummy
 - Education 0 = primary school/no education, 1 = junior high, 2 = senior high, 
3 = university/college
Ordered dummy
 - Marital status 0 = not married/divorced/widowed, 1 = married Dummy
 - Have children 0 = no children, 1 = have children Dummy
 - Social insurance membership 0 = not on social insurance, 1 = on social insurance Dummy
 - Live with family 0 = not live with family, 1 = live with family Dummy
 - Support from family/peers 0 = not satisfied, 1 = satisfied Dummy
Demographic characteristics
 - Place of stay 0 = live in Bandung city, 1 = live outside Bandung city Dummy
Clinical characteristics
 - CD4 cell count 0 = >349 cells/mm3, 1 = 150-349 cells/mm3, 2 = 50-149 cells/
mm3, 3 = 0-49 cells/mm3
Ordered dummy
 - OI 0 = not infected by OI, 1 = infected by OI Dummy
 - IDU history 0 = no history, 1 = with history Dummy
 - TB history 0 = no history, 1 = with history Dummy
 - Length of treatment 0 = less than 1 year, 1 = more than 1 year Dummy
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(BPS). Lastly, we used the discount rate of 3%25, 
and the exchange rate of Rp13,230/1US$.26 We 
then combined the estimation of productivity loss 
per person to the whole number of (estimated) 
drop out patients at the clinic and at national 
level. Table 2 summarizes the indicators used 
in the productivity loss analysis. The estimation 
of patients undergoing ART and drop out rate at 
national level were taken from Spiritia.8
RESULTS
Table 3 summarizes patient characteristics 
based on factors presented in Table 1. Most 
patients are at their productive age, and mostly 
are male, employed, and receive secondary or 
tertiary education. More than a half of patients 
are married and have children. Almost all of 
patients are living with their family and satisfied 
with peer support. Most patients visit the clinic 
for the first time with higher than 50 cells/mm3 
CD4 cell count, and around 60% of the patients 
have IDU history.
Table 2. Productivity loss calculation indicators
Items Values
Average CD 4 cell count, drop out 
patients (95% C.I)
123 (91–155)
Number of drop out HIV patients
 - Male/female 55
 - Female 29
 - National male** 9,510
 - National female** 2,506
Monthly wage24
 - Minimum US$ 97.38
 - Average US$ 144.91
Productive age 15 – 64 years 
(50 years) 
Time length for CD 4 cell count to reach approximately 
50 cells/mm3 after dropout*
 - IDU 3.42 years
 - Non IDU 3.67 years
IDU***
 - IDU male***
Dropout rate
 - Clinic rate 12.77%
 - National rate8 17.90%
Unemployment rate
 - Clinic rate (male)*** 36.36%
 - National rate8 6.10% 27
Female labor participation rate 
 - Clinic rate*** 31.03%
 - National rate8 51% 27
Exchange rate26 Rp 13,230/US$ 
Discount rate25 3%
* Calculated based on results from Meijerink et al.22
** Estimated based on Spiritia8
*** from drop out patients
Table 3. Patient characteristics (n=658)
Variable list Values
Patients who drop out 84 (12.77%)
Socioeconomic characteristics
 - Mean of age (95% C.I) 30 (29.7 – 30.6)
 - Male 443 (67.33%)
 - Employed 425 (64.59%)
 - Education (secondary and 
tertiary)
635 (96.50%)
 - Marital status (married) 393 (59.73%)
 - Have children 402 (61.09%)
 - Have social insurance 
membership
87 (13.22%)
 - Live with family 585 (88.81%)
 - Satisfied with support from 
family/peers 
625 (94.98%)
Demographic characteristics
 - Place of stay (live outside 
Bandung city)
236 (35.87%)
Clinical characteristics
 - CD4 cell count (<50 cells/mm3) 213 (32.37%)
 - OI 166 (25.23%)
 - IDU history 394 (59.88%)
 - TB history 163 (24.77%)
 - Length of treatment (>1 year) 583 (88.60%)
Factors Associated with Drop Out
Figure 1 presents the marginal effect of 
the probit regression result. From the factors 
associated with higher probability of drop out 
(and significant at 90%, 95%, or 99% C.I), we 
found that patients with under than 50 cells/mm3 
CD4 cell count had 8.7% higher probability of 
drop out compared with patients with higher than 
349 cells/mm3 CD4 cell count. This percentage 
decreased as we move up the CD 4 cell count 
groups.
From the factors associated with lower 
probability of dropping out (and significant at 
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90%, 95%, or 99% C.I), we found that patients 
who lived with family have 10.2% lower 
probability of drop out compared with patients 
who did not. Patients who were satisfied with 
support from family/peers, had 8.8% lower 
probability of dropping out, compared to those 
who were not satisfied. Patients who lived outside 
Bandung city, and patients who were diagnosed 
with TB were associated with lower probability 
of drop out compared to their counterparts. Those 
who have been undergoing treatment for more 
than 1 year had a lower probability of dropping 
out compared to those who were undergoing the 
treatment for less than one year.
Impact of Drop Out on Productivity Loss
Table 4 presents the productivity loss at 
the clinic level and at national level. Using 
clinic dropout rate, the estimated productivity 
loss over remaining productive lifetime for 
patients visiting clinic can reach US$18 million. 
Projecting the clinic dropout rate into the number 
of HIV patients on ARV at national level, the 
estimated productivity loss over remaining 
productive lifetime can reach US$191 million. 
Using the national dropout rate, these numbers 
can rise to US$365 million.
Figure 1. The econometric analysis result using probit regression, presented by the marginal effect results for each variables
Table 4. Estimated productivity loss over remaining 
productive lifetime (US$)
Items Amount
Per person (based on clinic estimate)
 - High estimate* 34,226
 - Low estimate** 23,001
Clinic estimation
 - High estimate* 18,607,499
 - Low estimate** 12,504,956
National estimation
Using clinic indicators
 - High estimate* 191,054,269
 - Low estimate** 128,395,829
Using national indicators (except for % of IDU)
 - High estimate* 365,041,113
 - Low estimate** 245,321,691
*using average wage, ** using minimum wage
DISCUSSION
This study has two aims. First it analyzes 
the factors associated with HIV patients dropout 
in the clinic. Second, it estimates the impact of 
HIV patients dropout on productivity loss over 
remaining productive lifetime at the clinic and 
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national level. Based on these objectives, five 
observations can be made.
First, as higher CD 4 cell count are associated 
with lower probability of drop out, in line with 
a study by Blutinger et al.21 in India, optimizing 
early ARV initiation at higher CD 4 cell count is 
warranted. The benefit of potential costs saving 
by providing early ART has been discussed in 
other studies28–31, and our study adds that it may 
also reduce the probability of dropout. One of 
the potential scale up sites are the community 
clinics, since patients are taking HIV test at 
this type of clinic at a much higher CD4 cell 
count compared to those visiting hospitals.32 In 
addition, accessing HIV service at the community 
level will reduce patients’ costs and increase 
adherence of ART.5,28,33,34 However, the potential 
budget impact of scaling up and providing early 
ART35,36, and the required community staff 
capacity37 should be carefully assessed. Given 
the current prevalence rate of Indonesian HIV 
epidemic (0.5% for adults age 15-49)38, it seems 
that scaling up ART at the community should be 
conducted at areas with high prevalence setting 
39,40 to have a large impact.
Second, our results show that living with 
family and peer support is significantly associated 
with lower probability of HIV patients dropout. 
Another study from Indonesia and some 
studies from other countries also have similar 
finding.15,17,19,20,41,42 Thus, it is clear that family/
peer support should be further enhanced to ensure 
treatment success in the long run. Finding the 
correct scheme to enhance family/peer support 
should be done carefully as not all schemes 
may work (e.g. use of pager).43 On the other 
hand, interventions such as text messaging, 
self-forming group of patients, modified directly 
observed therapy (mDOT), are able to support 
ART adherence.44–47 Indonesia should start 
to either adopt (or modify if necessary) these 
already proven interventions or come with a 
breakthrough approach to improve the current 
family/peer support for HIV patients.
Third, as patients with TB history is 
associated with lower probability of drop 
out, it is a plausible idea to integrate TB and 
HIV treatment. Studies have shown that this 
integration have a positive impact on patients 
and community48–50, and models from low-
and middle-income countries are available.51 
However, the infrastructures and the capacity of 
health care workers, need to be enhanced for this 
integration to work.51,52 Fortunately, this kind of 
integrated TB/HIV models are also increasing 
in Indonesia2, leading to more efficient service 
deliveries. Therefore, consistent monitoring and 
evaluation of this scheme is required to produce 
an even more efficient and better quality HIV/
TB integrated services.
Fourth, our study shows that patients with 
longer than a year length of treatment are 
associated with lower probability of drop out. 
This has an important implication because if 
we are able to reduce drop out rate and keep 
patients within the treatment, it will lead to an 
even lower probability of drop out rate, creating 
a continuous effect.
Fifth, the costs of productivity loss over 
remaining productive lifetime due to dropout can 
be high. In our case, it can reach US$365 million: 
0.042% of our gross domestic product (GDP) 
in 201353 or 1.36% of total health expenditure 
in the same period.54 We need to compare this 
productivity loss to the costs of treatment if 
patients are staying in the program. Based on 
the study by Siregar et al.28, the cost of treating a 
patient with ARV is approximately US$1,200 per 
patient per year for patients with CD4 cell count 
lower than 50 cells/mm3 (this cost decreases as 
the CD4 cell count increases). Multiplying this 
amount with the number of drop out patients 
at national level (using clinic dropout rate and 
the discount rate of 3%) for the rest of their life 
years (subtracting life expectancy55 with the 
age of drop out in the clinic) results in US$301 
million, lower than the productivity loss. Thus, it 
seems that keeping patients within the treatment 
program is less costly compared to losing them. 
In addition, the ART provides other benefits 
aside of treating HIV patients. It also acts as a 
prevention measure for HIV epidemic56,57 and 
will most likely prevent spending more costs. 
Furthermore, bear in mind that our productivity 
loss calculation is based only on productivity 
approach using average and minimum wage. 
As such, in showing the potential economic 
impact of HIV patients dropout, we have forgone 
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other important values such as those stemming 
from loss of/reduced quality of life, costs to 
family members, hospitalization costs, OI 
treatment costs, possible line 2 ART costs, and 
indirect costs. Therefore, we believe the actual 
economic impact of dropout should be much 
higher. However, we need to take into account 
the currently low health budget of Indonesia if 
we want to provide ART to all HIV patients.58
In addition to our main observations, an 
important finding, although it is not statistically 
significant, should be carefully noted. Our 
analysis shows that higher education is related 
with higher probability of drop out. This is the 
opposite of the results by Schilkowsky et al.20, 
Waldrop-Valverde et al.59, and Unge et al.42. We 
suggest to explore this finding further as it has 
an important implication. If indeed a higher 
education is associated with higher probability 
of dropout, then a specific intervention should be 
designed to target patients with higher education 
as more than 90% of the patients in our study 
belong to this group.
On the other note, the history of drug use, 
surprisingly, does not seem to have a significant 
influence on the drop out rate. This is supported 
by another study in the clinic13, although 
international studies show otherwise.59,60 This 
warrants further investigations since IDUs 
still hold a crucial role in the Indonesian HIV 
epidemic. 
Study Limitation
There are several limitations in our study. 
First, the analysis on factors associated with HIV 
patients drop out is specific to the clinic that we 
studied, although similar results are found in 
some other local and international studies. Other 
clinics in Indonesia, however, may have different 
patterns. Therefore, applying the same study in 
more clinics in different settings in Indonesia 
(e.g. region, culture, religion, and politics) may 
yield more varied result and may enrich the 
discussion.
Second, we assume that the drop out patients 
will not join other ART program at other clinics 
and that they will not seek treatment afterwards. 
Of course this may not be true to all patients, 
as some may visit other clinics to obtain ART 
once their disease has become more severe and 
they feel the need for treatment. A more detailed 
analysis following patients who drop out may 
provide further insight on the potential economic 
impact of HIV patients drop out.
Third, there are much incomplete data 
set per person in our database, cutting our 
observation from 8,184 to 658 patients. This, 
will have implication on our results, and 
having better dataset may have improved our 
findings. Regardless, given the current number 
of observation, we have managed to show the 
significant factors that influence the probability 
of HIV patients dropout, adding information 
for the clinic managers and/or policy makers in 
designing appropriate policy.
Fourth, our productivity loss calculation 
is based only on productivity approach using 
average and minimum wage. We believe actual 
economic impact of drop out should be much 
higher as we forgone important values such as 
loss of/reduced quality of life, costs to family 
members, and hospitalization costs. However, 
the purpose of our productivity loss analysis is 
to show the potential economic impact due to 
the drop out at its most basic state. Our study has 
shown this and clarifies that this amount can only 
be higher if it is further calculated.
CONCLUSION
Controlling drop out rate is crucial as the 
success of ART will increase QoL, productivity, 
and physical and emotional health which 
influences the survival of patients. This study 
has shown that higher CD 4 cell count, satisfied 
with family/peer support, have been in treatment 
longer than a year, and have TB history are 
associated with lower probability of HIV patients 
dropout. We have also presented the severity 
of dropout in terms of its consequences on 
productivity loss. The estimated productivity loss 
over productive lifetime due to dropout can reach 
US$312 million for IDU and US$306 million 
for non-IDU at national level. We recommend 
to optimize early ART, family/peer support, and 
TB/HIV service integration to reduce drop out 
rate and reduce its economic impact. 
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